Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Position Raised by Migdal Insurance & Financial Holdings Ltd.

Migdal Insurance & Financial Holdings Ltd. lifted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 26,035,422 shares of the company’s stock after buying an additional 569,412 shares during the quarter. Teva Pharmaceutical Industries makes up 8.2% of Migdal Insurance & Financial Holdings Ltd.’s investment portfolio, making the stock its largest holding. Migdal Insurance & Financial Holdings Ltd. owned approximately 2.30% of Teva Pharmaceutical Industries worth $573,822,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Stifel Financial Corp raised its position in shares of Teva Pharmaceutical Industries by 54.0% during the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after acquiring an additional 23,283 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its position in shares of Teva Pharmaceutical Industries by 7.2% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock worth $10,983,000 after acquiring an additional 33,277 shares in the last quarter. Thrivent Financial for Lutherans raised its position in shares of Teva Pharmaceutical Industries by 21.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock worth $4,046,000 after acquiring an additional 40,218 shares in the last quarter. Sio Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $24,314,000. Finally, CWA Asset Management Group LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $3,340,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 0.6 %

Shares of TEVA stock opened at $17.31 on Friday. The business’s 50 day moving average is $20.03 and its two-hundred day moving average is $18.50. Teva Pharmaceutical Industries Limited has a twelve month low of $11.83 and a twelve month high of $22.80. The company has a market capitalization of $19.61 billion, a P/E ratio of -11.94, a price-to-earnings-growth ratio of 1.43 and a beta of 0.71. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 40.20% and a negative net margin of 9.91%. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.62 EPS for the current year.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. UBS Group cut their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Barclays dropped their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Finally, Piper Sandler raised their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $23.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.